Literature DB >> 28194056

Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype.

Dalia Salem1, Sherin Abd El-Aziz1, Nadia El-Menshawy1, Tarek Abouzeid1, Mohamed Ebrahim2.   

Abstract

Mutation in IDH1 gene was suggested to be associated with bad prognosis in cytogenetically normal AML (CN-AML). However, there are conflicting data about its prognostic impact. Besides, its prevalence and prognostic significance in Egyptian patients still not fully stated. We aimed to assess the prevalence of IDH1R132 mutation in Egyptian CN-AML patients, its correlation with FAB subtypes, and clinical outcome of those patients. Sequencing of amplified IDH1 gene exon four from 50 patients was performed to detect codon R132 point mutation. High prevalence of IDH1 mutation was detected in our patients (9/50, 18 %). Mutated IDH1R132 was associated with older age and higher platelets count (p = 0.04 and 0.01 respectively). The most common FAB subtype associated with mutated IDH1R132 was AML-M2 followed by M4. In multivariate analysis, IDH1R132 mutation was found as independent prognostic variable. It was significantly associated with lower CR and shorter OS (p = 0.06 and 0.009 respectively).

Entities:  

Keywords:  IDH; Mutations in AML; Normal karyotype AML

Year:  2016        PMID: 28194056      PMCID: PMC5280846          DOI: 10.1007/s12288-016-0649-z

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  28 in total

1.  Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

Authors:  Katharina Wagner; Frederik Damm; Gudrun Göhring; Kerstin Görlich; Michael Heuser; Irina Schäfer; Oliver Ottmann; Michael Lübbert; Wolfgang Heit; Lothar Kanz; Günter Schlimok; Aruna A Raghavachar; Walter Fiedler; Hartmut H Kirchner; Wolfram Brugger; Manuela Zucknick; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Jürgen Krauter
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

Review 2.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Susan P Whitman; Clara D Bloomfield
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

3.  Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients.

Authors:  Yiqun Zhang; Hui Wei; Min Wang; Lei Huai; Yingchang Mi; Yizhi Zhang; Dong Lin; Bingcheng Liu; Wei Li; Chunlin Zhou; Qing Rao; Jianxiang Wang
Journal:  Leuk Res       Date:  2011-02-12       Impact factor: 3.156

4.  Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.

Authors:  Wen-Chien Chou; Hsin-An Hou; Chien-Yuan Chen; Jih-Luh Tang; Ming Yao; Woei Tsay; Bor-Shen Ko; Shang-Ju Wu; Shang-Yi Huang; Szu-Chun Hsu; Yao-Chang Chen; Yen-Ning Huang; Yi-Chang Chang; Fen-Yu Lee; Ming-Chi Liu; Chia-Wen Liu; Mei-Hsuan Tseng; Chi-Fei Huang; Hwei-Fang Tien
Journal:  Blood       Date:  2010-01-22       Impact factor: 22.113

5.  Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers.

Authors:  Mi Ran Kang; Min Sung Kim; Ji Eun Oh; Yoo Ri Kim; Sang Yong Song; Seong Il Seo; Ji Youl Lee; Nam Jin Yoo; Sug Hyung Lee
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

6.  Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.

Authors:  Verena Ingeborg Gaidzik; Richard Friedrich Schlenk; Simone Moschny; Annegret Becker; Lars Bullinger; Andrea Corbacioglu; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2009-02-12       Impact factor: 22.113

7.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

8.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Authors:  Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Marianne Habdank; Jan Krönke; Lars Bullinger; Daniela Späth; Sabine Kayser; Manuela Zucknick; Katharina Götze; Heinz-A Horst; Ulrich Germing; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 50.717

9.  Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.

Authors:  Marta Fernandez-Mercado; Bon Ham Yip; Andrea Pellagatti; Carwyn Davies; María José Larrayoz; Toshinori Kondo; Cristina Pérez; Sally Killick; Emma-Jane McDonald; María Dolores Odero; Xabier Agirre; Felipe Prósper; María José Calasanz; James S Wainscoat; Jacqueline Boultwood
Journal:  PLoS One       Date:  2012-08-09       Impact factor: 3.240

10.  Metabolic enzymes as oncogenes or tumor suppressors.

Authors:  Craig B Thompson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079

View more
  3 in total

1.  Molecular Profiling of Kenyan Acute Myeloid Leukemia Patients.

Authors:  Mercy Gatua; Mohsen Navari; Matilda Ong'ondi; Noel Onyango; Serah Kaggia; Emily Rogena; Giuseppe Visani; Nicholas A Abinya; Pier Paolo Piccaluga
Journal:  Front Genet       Date:  2022-06-28       Impact factor: 4.772

2.  The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients.

Authors:  Mario Petrini; Sara Galimberti; Serena Salehzadeh; Francesca Guerrini; Umberto Pizzano; Susanna Grassi; Elena Ciabatti; Lorenzo Iovino; Gabriele Buda; Francesco Caracciolo; Edoardo Benedetti; Enrico Orciuolo; Matteo Pelosini; Giovanni Consani; Giovanni Carulli; Maria Rita Metelli; Francesca Martini; Francesco Mazziotta; Elisa Mazzantini; Pietro Rossi; Rita Tavarozzi; Federica Ricci
Journal:  Cancer Cell Int       Date:  2019-04-04       Impact factor: 5.722

3.  PRKD2 Promotes Progression and Chemoresistance of AML via Regulating Notch1 Pathway.

Authors:  Qian Liu; Wei Li; Ying Zhou; Jimo Jian; Shijie Han; Chao Liu; Wei Li; Xunxun Zhu; Daoxin Ma; Min Ji; Chunyan Ji
Journal:  Onco Targets Ther       Date:  2019-12-12       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.